No abstract available.
Dehydroepiandrosterone*

Effects of HPCD and PVP in transdermal delivery systems prepared by combination of Eudragit E100, medium chain triglyceride and isopropyl alcohol on DHEA skin permeation properties were studied. The results were shown that HPCD and PVP have good effects both in permeation properties of DHEA in vitro through pig’s ear stratum corneum and the release properties of DHEA to skin surface. The highest permeation rate reported was about 3.88 mg/cm2.h that indicated the ability of using the patches as a dosage form for administration of DHEA
Dehydroepiandrosterone ; Cosmetic Techniques ; pharmacy

The effects of the type of plasticizers and concentration of active substance on skin permeation properties of DHEA from patches were studied. The results showed that propylen glycol (as a plasticizer) could improve the skin permeation rate of DHEA significantly comparing with medium chain triglycerid. When the concentrations of DHEA in the patch increased, the skin permeation rates of DHEA increased linearly until DHEA solubility saturates in the matrix. But while the concentrations of DHEA in the patch were higher, DHEA could change in to the crystalline form that makes decreasing of the skin permeation rate of DHEA
Dehydroepiandrosterone ; Pharmaceutical Preparations

To study in vitro usability of Transdermal Therapeutic Systems (TTS) dehydroepiandrosteron (DHEA) on pig's ear skin. Results showed that: there was correlation about DHEA permeation between human and pig's ear skin. DHEA permeation speed was linear proportional with square root of time and the DHEA content in TTS. DHEA permeation speed via human skin had linear correlation with permeation speed via pig's ear skin with angular co-efficient 0.74; this showed that pig's ear skin can be used for exploratory research on establishing formulation of transdermal drugs. Pig skins are available material and easy to collect with large amount. However, this result also showed that permeation ability of human skin is lower than pig’s ear skin
Dehydroepiandrosterone ; Administration, Cutaneous ; Therapeutics

OBJECTIVE: Dehydroepiandrosterone sulphate (DHEAS), the major steroidal product of the human adrenal, is abnormally low in patients with SLE. Moreover, a recent study confirms a positive effect of the precursor DHEA on the disease course in SLE, which supports an etiologically important role of the hormone on SLE. The aim of this study is to search for an interrelation between clinical manifestations, laboratory findings, and disease activities and DHEAS in patients with SLE. METHOD: DHEAS were measured by radioimmunoassay kit using 125I-labeled DHEA-SO4 antibody-coated tube in the serum of 48 patients with SLE and in 46 control subjects. Laboratory findings, clinical symptoms, signs and SLE disease activity index (SLEDAI) in SLE patients were evaluated at blood sampling time. RESULTS: DHEAS was lower in patients with SLE compared to controls (45.60+/-42.62 mug/dL vs 101.55+/-56.54 mug/dL, p<0.005). The serum DHEAS levels were significantly negative correlation with SLEDAI (r=-0.333, p<0.05). There were significantly negative correlations between daily steroid dose and DHEAS (r=-0.384, p=0.012), and the amount of steroid used during previous 2 months and DHEAS (r=-0.011, p=0.011). CONCLUSIONS: Patients with SLE have low levels of DHEAS and significant negative correlation between SLEDAI, steroid dose and DHEAS.
Dehydroepiandrosterone* ; Female ; Humans ; Lupus Erythematosus, Systemic* ; Radioimmunoassay

OBJECTIVE: To investigate the relationship between serum dehydroepiandrosterone sulfate (DHEAS) or free testosterone (FT) levels and aging. METHODS:One hundred and thirty one women without androgen excess symptoms such as oligomenorrhea or amenorrhea or hirsutism were recruited for measuring serum DHEAS, FT levels by radioimmunoassay. A P-value <0.05 was considered to be significant statistically. RESULTS: The levels of DHEAS were 211.39+/-33.01 microg/dL (twenties, n=10), 127.99+/-11.79 microg/dL (thirties, n=31), 94.30+/-7.49 microg/dL (forties, n=57) and 71.79+/-5.71 microg/dL (over fifties, n=33) respectively (mean+/-SE, P<0.001). The levels of FT were 3.98+/-0.94 pg/ml (twenties, n=10), 3.37+/-0.47 pg/mL (thirties, n=31), 2.68+/-0.30 pg/mL (forties, n=57) and 1.97+/-0.28 pg/mL (fifties, n=33) respectively (mean+/-SE, P=0.030). Mean value declining of DHEAS (r=-0.48865, P<0.0001) was bigger than those of FT (r=-0.29334, P<0.0007). CONCLUSION: Both DHEAS and FT levels decline with age and DHEAS decreases more steeply than FT.
Aging ; Amenorrhea ; Dehydroepiandrosterone ; Dehydroepiandrosterone Sulfate ; Female ; Hirsutism ; Humans ; Oligomenorrhea ; Radioimmunoassay ; Testosterone

OBJECTIVE: To investigate the relationship between serum dehydroepiandrosterone sulfate (DHEAS) or free testosterone (FT) levels and aging. METHODS:One hundred and thirty one women without androgen excess symptoms such as oligomenorrhea or amenorrhea or hirsutism were recruited for measuring serum DHEAS, FT levels by radioimmunoassay. A P-value <0.05 was considered to be significant statistically. RESULTS: The levels of DHEAS were 211.39+/-33.01 microg/dL (twenties, n=10), 127.99+/-11.79 microg/dL (thirties, n=31), 94.30+/-7.49 microg/dL (forties, n=57) and 71.79+/-5.71 microg/dL (over fifties, n=33) respectively (mean+/-SE, P<0.001). The levels of FT were 3.98+/-0.94 pg/ml (twenties, n=10), 3.37+/-0.47 pg/mL (thirties, n=31), 2.68+/-0.30 pg/mL (forties, n=57) and 1.97+/-0.28 pg/mL (fifties, n=33) respectively (mean+/-SE, P=0.030). Mean value declining of DHEAS (r=-0.48865, P<0.0001) was bigger than those of FT (r=-0.29334, P<0.0007). CONCLUSION: Both DHEAS and FT levels decline with age and DHEAS decreases more steeply than FT.
Aging ; Amenorrhea ; Dehydroepiandrosterone ; Dehydroepiandrosterone Sulfate ; Female ; Hirsutism ; Humans ; Oligomenorrhea ; Radioimmunoassay ; Testosterone

PURPOSE: Fatigue, energy loss, feeling of helplessness, poor appetite, pain besides general weakness are major symptoms presented to terminally ill cancer patients. These symptoms are similar to those that appeared with adrenal insufficiency. Also, for terminally ill cancer patients who are hospitalized for palliative care, opioid agents are prescribed to control moderate to severe pain. We studied the relationship of opioid agents and adrenal insufficiency. METHODS: From November 2013 through June 2014, we monitored the serum level of cortisol and dehydroepiandrosterone sulfate (DHEAS, serum) in 55 cancer patients who were over 18 years old and were treated at a hospice center. We also checked the treatment period and dosage of opioid agents. RESULTS: The DHEAS level, treatment period and dosage of opioid agents did not have significant correlation. Correlation between the serum cortisol level and the opioid agent treatment period was not significant either, but the serum cortisol level was positively correlated with the dosage of opioid agents (P value 0.0322). CONCLUSION: This study did not identify a novel link between treatment period, dosage of opioid agents and adrenal insufficiency. But, the DHEAS level was mostly below the normal level in patients who were treated with opioid agents.
Adrenal Insufficiency ; Analgesics, Opioid* ; Appetite ; Dehydroepiandrosterone Sulfate ; Dehydroepiandrosterone* ; Fatigue ; Hospices ; Humans ; Hydrocortisone* ; Palliative Care ; Terminally Ill

PURPOSE: This study aimed to determine the effects of the long-term use of dehydroepiandrosterone sulfate (DHEAS) on rat prostates and testes as well as on serum testosterone and DHEAS levels. MATERIALS AND METHODS: Thirty male rats aged 4 to 5 months were studied. A DHEAS suspension of 5 mg/kg per rat was administered orally to the 15 rats in the experimental group 5 times a week, whereas saline was administered concurrently to the 15 rats in the control group. Intracardiac blood samples were drawn to determine hormone levels, and histological samples of prostate and testes were evaluated under light microscopy. RESULTS: At the end of the 6-month study period, histological examinations performed on prostate preparations showed that the atrophy score of the experimental group was significantly lower than the scores of the sham and control groups (p<0.001 and p<0.001, respectively). The serum total testosterone and DHEAS levels of the rats in the study group were significantly increased (p<0.001). CONCLUSIONS: In our study, we determined that the long-term use of DHEAS does not have any detrimental effects on the prostate or the testis; on the contrary, it protects the prostate from atrophy, which is imperative for the continuation of fertility as well as for increasing serum testosterone and DHEAS levels.
Aged ; Aging ; Animals ; Atrophy ; Dehydroepiandrosterone ; Dehydroepiandrosterone Sulfate ; Fertility ; Humans ; Light ; Male ; Prostate ; Rats ; Salicylamides ; Testis ; Testosterone

OBJECTIVETo investigate the relationship of serum dehydroepiandrosterone (DHEA) levels and female precocious puberty.

METHODSThe serum levels of DHEA and dehydroepiandrosterone sulfate (DHEAS) were measured by ELISA in 60 idiopathic central precocious puberty (ICPP) girls, 62 premature thelarche (PT) girls and 31 age-matched health prepuberty girls. Bone age,volume of uterus and ovary, DHEA and DHEAS were re-measured in 3, 12 months after treatment with Diphereline in ICPP girls.

RESULT(1) The Log(DHEA) and Log(DHEAS) were (0.81 +/-0.36)microg/L and (2.31 +/-0.31)microg/L in ICPP group, (0.72 +/-0.30)microg/L and (2.31 +/-0.28)mg/L in PT group, and (0.32 +/-0.26)microg/L and (2.16+/-0.27)microg/L in controls (P <0.05). However, no significant differences were found between ICPP and PT group (P >0.05). Moreover, the serum levels of DHEA and DHEAS in precocious puberty girls with Tanner III stage were significant higher than those with Tanner II stage (P <0.05). (2) With bivariate correlation analysis, Log(DHEA) was positively correlated with height, bone age, volume of uterus and ovary (r=0.429, 0.339, 0.217, 0.282; all P<0.05), while no significant correlation with Log(LH peak), Log(FSH peak) and BMI (r=0.135, -0.165, 0.059). Log(DHEAS) was positively correlated with height,bone age and volume of ovary (r=0.319, 0.210, 0.181; P <0.05), while no correlated with Log(LH peak), Log(FSH peak), volume of uterus and BMI (r=0.012, -0.173, 0.146 and 0.081 respectively). (3) Serum Log (DHEA) and Log(DHEAS) of 32 ICPP were decreased from (0.83 +/-0.35) microg/L and (2.27 +/-0.30)microg/L to (0.68 +/-0.44)microg/L and (2.11 +/-0.43)microg/L (P<0.05) 3 months after treatment. The serum Log(DHEA) and Log(DHEAS) in 12 months after treatment were (0.78 +/-0.30)microg/L and (2.40+/-0.34)microg/L, which was not significantly different with that before treatment (P>0.05). However, the volume of uterus and ovary, bone age/age in 12 months after treatment were significantly different with those before treatment (2.82 +/-1.52 compared with 1.09 +/-0.50 ml, 3.15 +/-1.13 compared with 1.18 +/-0.42 ml, 1.43 +/-0.23 compared with 1.25 +/-0.12, all P<0.05).

CONCLUSION(1) The serum levels of DHEA and DHEAS are increased in precocious puberty girls with the development of Tanner stage. (2) Serum levels of DHEA and DHEAS are declined transiently when the hypothalamic-pituitary-gonadal axis is inhibited. (3) Serum DHEA is associated with the acceleration of growth and bone age in precocious puberty girls.

Child ; Dehydroepiandrosterone ; blood ; Dehydroepiandrosterone Sulfate ; blood ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Puberty, Precocious ; blood